Founded in 1952, China Chemical & Pharmaceutical Co., Ltd. (CCPC) is dedicated to the innovation, research and development, manufacturing, and upgrade of services in the pharmaceutical industry. Since its establishment, CCPC has made numerous advances in the development of generic pharmaceutical and healthcare products for use in humans and animals. Widely used in every hospital and family household, the company’s advanced medical and health products help ensure better health and quality of life.

The CCPC scope of operations is primarily centered on generic pharmaceuticals. In an attempt to explore global generic markets, CCPC is closely collaborating with its sister companies as an integrated pharmaceutical company. At this point, our strategy is to provide niche and high manufacturing complexity API/generic drugs and the so-called 505(b)(2) new drugs (such as new route of administration, new derivatives, new use, etc.) to the US market. Our initial attempts are to develop the technology in Asia (some may have already been developed) and then move the technology into the USA and work with our US collaborative partners CMOs and CROs to get regulatory approval. At the same time, CCPC is actively trying to partner with overseas pharmaceutical companies or wholesalers to market and distribute our niche products in specific territories.

CCPC Production Division

Our Production Division encompasses the Hsinfeng Plant, Taichung Plant, Tainan Plants II and III, all of which are PIC/S GMP pharmaceutical manufacturing plants approved by the Department of Health in Taiwan, and Tainan Plant II also approved by the U.S. FDA, producing pharmaceuticals such as ordinary pharmaceutical cooling gels, sterile powders, Ampoules, Vials, SVP, LVP, liquids, ointments and suppositories, tablets, capsules, powders, penicillin antibiotics, and penicillin cooling gels for animals, cephalosporin sterile powder.

The Hsinfong Plant, Hsinfong Plant II and Taichung Plant have been accredited by Japan’s PMDA, and products are being exported to the Japanese market. In 2014, expansion of the injection, solution and ointment lines at Tainan Plant I was completed, and the plant also passed the GMP inspection for veterinary drug plants. It is a specialized veterinary drug plant established based on the cGMP framework.

With years of endeavor through independent development, R&D partnerships, and technology introduction, CCPC now possesses special osmotic pump, repeated release, matrix, delayed release, and multiple layer device controlled release technologies and is capable of mass production of all types of pharmaceuticals and logistics management. It also has a top-end quality management system and R&D team. Besides being capable of researching and developing innovative products and producing high quality products, CCPC also provides import-license authorized development, registration, and contract R&D and production. For example, its contract manufacture clients include Takeda Pharmaceutical, Yamanouchi Pharmaceutical, Shionogi, Daiichi, Taiwan Sankyo Pharmaceutical, Ajinomoto, J&J, Roche, SORM, Try-X, and Impax (contract research).